Sulbactam-durlobactam found effective and well-tolerated against hospital-acquired pneumonia
USA: A novel combination antibiotic sulbactam-durlobactam is non-inferior to the best currently approved treatment for combating dangerous pneumonia, a recent Rutgers researcher-led trial has revealed. The data showed that sulbactam–durlobactam was non-inferior to colistin, both agents given in combination with imipenem–cilastatin, for the primary endpoint of 28-day all-cause...
USA: A novel combination antibiotic sulbactam-durlobactam is non-inferior to the best currently approved treatment for combating dangerous pneumonia, a recent Rutgers researcher-led trial has revealed.
The data showed that sulbactam–durlobactam was non-inferior to colistin, both agents given in combination with imipenem–cilastatin, for the primary endpoint of 28-day all-cause mortality. Also, sulbactam–durlobactam was well tolerated and could be an effective intervention to lower mortality from serious infections caused by carbapenem-resistant ABC (Acinetobacter baumannii–calcoaceticus complex), including multidrug-resistant strains.
The findings have led a unanimous expert committee to recommend that the Food and Drug Administration (FDA) approve the new drug, which could be available this summer to combat the often-fatal pneumonia strain known as carbapenem-resistant ABC, typically acquired in hospitals.
“Antibiotic-resistant infections are a serious and persistent problem at healthcare facilities, and the [Centers for Disease Control] ranks ABC at the highest level on its threat list,” said Keith Kaye, chief of the Division of Allergy, Immunology and Infectious Disease at Robert Wood Johnson Medical School and first author of the trial report in The Lancet Infectious Diseases. “An estimated 8,500 hospital-acquired cases killed 700 patients and cost $280 million in 2019, so we greatly needed a breakthrough treatment like sulbactam-durlobactam.”
The trial gave imipenem–cilastatin to 181 patients with laboratory-confirmed ABC and then randomized them to additional treatment with either sulbactam–durlobactam or the best existing treatment, an antibiotic called colistin. Mortality due to multiple causes after 28 days was 12 of 63 (19 percent) in the sulbactam–durlobactam group and 20 of 62 (32 percent) in the colistin group.
The trial was large enough to prove that sulbactam-durlobactam prevents at least as many fatalities as colistin but not large enough to prove its superiority in this trial will persist in real-world use, though it may.
The trial results did prove that sulbactam-durlobactam beats colistin in one crucial respect: tolerability. Kidney injury, serious adverse events and all treatment-related adverse events were significantly lower for patients who received sulbactam-durlobactam than for patients who received colistin.
Another advantage of the novel antibiotic is dosing. All patients receive the same injectable dose of sulbactam–durlobactam. Doses of colistin in the study, on the other hand, varied with patient weight, so it’s considerably easier for providers to prescribe or administer the wrong amount.
As its name implies, sulbactam-durlobactam combines two drugs. Sulbactam has been approved for use since 1986, but durlobactam is new and has yet to win approval. That could change soon, however. The FDA’s Antimicrobial Drugs Advisory Committee reviewed advance results of the new trial, along with earlier studies, and recommended on April 17 that the FDA approve the new combination for ABC treatment.
FDA officials are free to reject such recommendations but almost always follow recommendations from advisory committees, which comprise independent experts on particular classes of disease and medication.
“If all moves quickly, infected patients could begin receiving sulbactam-durlobactam as part of normal clinical care the second half of this year,” Kaye said. “Unfortunately, sulbactam-durlobactam isn’t the sort of wide-spectrum antibiotic that could prove effective in treating a wide variety of antibiotic-resistant infections, but it’s very good at treating this particularly dangerous one, and that’s a significant win.”
Prof Keith S Kaye, Prof Andrew F Shorr, Prof Richard G Wunderink, Prof Bin Du, Gabrielle E Poirier, Khurram Rana, Alita Miller, Drew Lewis, John O'Donnell, Lan Chen, Harald Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac, Published: May 11, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00184-6.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: email@example.com. Contact no. 011-43720751